BS_2XD3MNKD
Glial-neuronal tumor NOS
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Glial-neuronal tumor NOS
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Glial-neuronal tumor NOS
- overall_survival_months
- 13.501971090670171
- age_years
- 17.126
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.421
- PANCREAS_BETA_CELLS+0.272
- SPERMATOGENESIS+0.233
- BILE_ACID_METABOLISM+0.194
- MYOGENESIS+0.090
- ESTROGEN_RESPONSE_LATE-0.032
- APICAL_SURFACE-0.040
- CHOLESTEROL_HOMEOSTASIS-0.054
- XENOBIOTIC_METABOLISM-0.075
- APICAL_JUNCTION-0.101
Top 10 suppressed
- MYC_TARGETS_V1-0.627
- MYC_TARGETS_V2-0.594
- UNFOLDED_PROTEIN_RESPONSE-0.580
- DNA_REPAIR-0.526
- E2F_TARGETS-0.522
- ANGIOGENESIS-0.519
- OXIDATIVE_PHOSPHORYLATION-0.515
- INTERFERON_GAMMA_RESPONSE-0.489
- TNFA_SIGNALING_VIA_NFKB-0.489
- G2M_CHECKPOINT-0.488
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0T17SY47 | low-grade glioma | — | 0.973 |
| 2 | MNG540 | — | — | 0.961 |
| 3 | BS_063ERW0R | pilocytic astrocytoma | — | 0.959 |
| 4 | BS_CQSAJ7BF | DNET | — | 0.952 |
| 5 | BS_QC3XCE6X | low-grade glioma | — | 0.951 |
| 6 | MNG44 | — | — | 0.951 |
| 7 | MNG226 | — | — | 0.951 |
| 8 | SRR602927 | GTEX | — | 0.950 |
| 9 | 8ad884fa-e426-4bc0-960d-08db42d341da | — | — | 0.949 |
| 10 | MNG1280 | — | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.421 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.272 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.233 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.194 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |